AAAAAA
Results:
1-16
|
Results: 16
Authors:
Porter, AT
Ben-Josef, E
Citation: At. Porter et E. Ben-josef, Humoral mechanisms in prostate cancer: A role for FSH, UROL ONCOL, 6(4), 2001, pp. 131-138
Authors:
Porter, AT
Citation: At. Porter, Painful osteoblastic metastases: The role of nuclear medicine - The Silberstein article reviewed, ONCOLOGY-NY, 15(2), 2001, pp. 169-170
Authors:
Ben-Josef, E
Porter, AT
Han, S
Mertens, W
Chuba, P
Fontana, J
Hussain, M
Citation: E. Ben-josef et al., Neoadjuvant estramustine and etoposide followed by concurrent estramustineand definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results, INT J RAD O, 49(3), 2001, pp. 699-703
Authors:
Gospodarowicz, MK
Milosevic, MF
Warde, P
Porter, AT
Citation: Mk. Gospodarowicz et al., Clinical situations for the role of radiation therapy in the treatment of bladder cancer, CURR CLIN U, 2001, pp. 327-341
Authors:
Hart, KB
Wood, DP
Tekyi-Mensah, S
Porter, AT
Pontes, JE
Forman, JD
Citation: Kb. Hart et al., The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy, INT J RAD O, 45(5), 1999, pp. 1235-1238
Authors:
Ben-Josef, E
Shamsa, F
Youssef, E
Porter, AT
Citation: E. Ben-josef et al., External beam radiotherapy for painful osseous metastases: Pooled data dose response analysis, INT J RAD O, 45(3), 1999, pp. 715-719
Authors:
Garde, SV
Basrur, VS
Li, L
Finkelman, MA
Krishan, A
Wellham, L
Ben-Josef, E
Haddad, M
Taylor, JD
Porter, AT
Tang, DG
Citation: Sv. Garde et al., Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis, PROSTATE, 38(2), 1999, pp. 118-125
Authors:
Li, L
Zhu, ZY
Joshi, B
Porter, AT
Tang, DG
Citation: L. Li et al., A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies, ANTICANC R, 19(1A), 1999, pp. 51-60
Authors:
Li, L
Zhu, ZY
Joshi, B
Zhang, C
Johnson, CR
Marnett, LJ
Honn, KV
Crissman, JD
Porter, AT
Tang, DG
Citation: L. Li et al., A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies, ANTICANC R, 19(1A), 1999, pp. 61-69
Authors:
Maughan, RL
Brambs, B
Porter, AT
Forman, JD
Citation: Rl. Maughan et al., The cost-effectiveness of mixed beam neutron-photon radiation therapy in the treatment of adenocarcinoma of the prostate, STRAH ONKOL, 175, 1999, pp. 104-107
Authors:
Maughan, RL
Chuba, P
Porter, AT
Ben-Josef, E
Lucas, DR
Bjarngard, BE
Citation: Rl. Maughan et al., Mass energy-absorption coefficients and mass collision stopping powers forelectrons in tumors of various histologies, MED PHYS, 26(3), 1999, pp. 472-477
Authors:
Ben-Josef, E
Yang, SY
Ji, TH
Bidart, JM
Garde, SV
Chopra, DP
Porter, AT
Tang, DG
Citation: E. Ben-josef et al., Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR), J UROL, 161(3), 1999, pp. 970-976
Authors:
Joshi, B
Li, L
Taffe, BG
Zhu, ZY
Wahl, S
Tian, H
Ben-Josef, E
Taylor, JD
Porter, AT
Tang, DG
Citation: B. Joshi et al., Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain, CANCER RES, 59(17), 1999, pp. 4343-4355
Authors:
Porter, AT
Hart, KB
Citation: At. Porter et Kb. Hart, Radiation therapy in the treatment of localized/organ-confined prostate cancer, TEXTBOOK OF PROSTATE CANCER, 1999, pp. 231-247
Authors:
Roach, M
Porter, AT
Citation: M. Roach et At. Porter, Neoadjuvant hormonal radiotherapy for prostate cancer: Status and controversies, MOL UROL, 2(3), 1998, pp. 111-117
Authors:
Fair, WR
Porter, AT
Roach, M
Citation: Wr. Fair et al., Neoadjuvant hormonal radiotherapy for prostate cancer: Status and controversies - Discussion, MOL UROL, 2(3), 1998, pp. 119-119
Risultati:
1-16
|